Ocular Therapeutix Files 2025 Proxy Statement
Ticker: OCUL · Form: DEF 14A · Filed: Apr 29, 2025 · CIK: 1393434
| Field | Detail |
|---|---|
| Company | Ocular Therapeutix, Inc (OCUL) |
| Form Type | DEF 14A |
| Filed Date | Apr 29, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, executive-compensation, corporate-governance
TL;DR
OCUL proxy out: exec comp details for Mattessich & Dugel, equity awards in focus.
AI Summary
Ocular Therapeutix, Inc. filed its DEF 14A on April 29, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation and other corporate governance matters. Key individuals mentioned include members like Mattessich and Dugel, with compensation data related to equity awards granted and vested during the covered years.
Why It Matters
This filing provides shareholders with crucial information regarding executive compensation and corporate governance, enabling informed voting decisions on proposals at the upcoming annual meeting.
Risk Assessment
Risk Level: medium — DEF 14A filings are routine but can reveal changes in executive compensation or governance that may impact investor confidence and stock performance.
Key Numbers
- 20250429 — Filing Date (Indicates when the proxy statement was submitted to the SEC.)
- 20250611 — Period of Report (Defines the period the filing pertains to, typically the date of the annual meeting.)
- 2024-12-31 — Fiscal Year End (The end date of the fiscal year for which compensation data is reported.)
Key Players & Entities
- OCULAR THERAPEUTIX, INC (company) — Filer
- Mattessich (person) — Executive/Director
- Dugel (person) — Executive/Director
- 15 CROSBY DRIVE (address) — Business and Mail Address
- BEDFORD, MA (location) — Business and Mail Address
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose is to provide shareholders with information regarding executive compensation, director nominations, and other corporate governance matters ahead of the annual meeting.
Who are the key individuals whose compensation is detailed in this filing?
Key individuals mentioned in relation to compensation data include members such as Mattessich and Dugel.
What type of compensation is being highlighted for these individuals?
The filing details equity awards granted and vested, including year-end fair value of equity awards granted in covered years and those outstanding/unvested.
When is the period of report for this filing?
The period of report is June 11, 2025.
What is the company's Standard Industrial Classification (SIC) code?
The company's SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 29, 2025 by Mattessich regarding OCULAR THERAPEUTIX, INC (OCUL).